NMR-Based Lipid Metabolite Profiles to Predict Outcomes in Patients Undergoing Interventional Therapy for a Hepatocellular Carcinoma (HCC): A Substudy of the SORAMIC Trial

Abstract

Background: This exploratory study aimed to evaluate lipidomic and metabolomic profiles in patients with early and advanced HCCs and to investigate whether certain metabolic parameters may predict the overall survival in these patients. Methods: A total of 60 patients from the prospective, randomized-controlled, multicenter phase II SORAMIC trial were included in this substudy; among them were 30 patients with an early HCC who underwent radiofrequency ablation combined with sorafenib or a placebo and 30 patients with an advanced HCC who were treated with a selective internal radiation therapy (SIRT) plus sorafenib vs. sorafenib alone. The blood serum of these patients was analyzed using a standardized nuclear magnetic resonance (NMR) platform. All tested metabolites were correlated with the overall survival. Results: The overall survival (OS) was significantly higher in patients with an early HCC (median OS: 34.0 months) compared with patients with an advanced HCC (median OS: 12.0 months) (p < 0.0001). Patients with high serum concentrations of myo-inositol (MI) had a higher overall survival compared with patients with low concentrations (21.6 vs. 13.8 months) with a Pearson correlation coefficient of 0.331 (p = 0.011). Patients with high serum concentrations of dimethylamine had a higher overall survival compared with patients with low concentrations (25.1 vs. 19.7 months) with a Pearson correlation coefficient of 0.279 (p = 0.034). High concentrations of total cholesterol, LDL-cholesterol and LDL particles (LDL-P) were associated with a decreased overall survival. Conclusions: NMR-based lipidomic and metabolomic profiling has the potential to identify individual metabolite biomarkers that predict the outcome of patients with an HCC exposed to non-invasive therapeutic management.

Hepatitis B-related hepatocellular carcinoma: classification and prognostic model based on programmed cell death genes

“…Previous studies have reported that dysregulated metabolism is a hallmark of cancer, especially in HCC (16)(17)(18), for example, glycolytic pathway (9) and lipid metabolism pathway (19) were found to be upregulated in HCC, and targeting these pathways may have therapeutic potential. In our study, we performed more detailed research and found that metabolic pathways were activated or inhibited in different immune subtypes of HBV-HCC.…”

Metabolomics in hepatocellular carcinoma: From biomarker discovery to precision medicine

“…The first study recruited 60 HCC patients to identify serum metabolites that were associated with therapeutic outcomes of HCC after TACE treatment. It was found that higher levels of total cholesterol, low density lipoprotein cholesterol, and low-density lipoprotein particles were associated with a poorer overall survival ( 106 ). Another 1 H-NMR-based study aimed to investigate the metabolic alterations in plasma of recurrent or metastatic HCC patients after TACE treatment or post-surgery.…”